OncoImmunology, June 2020

Generation of highly activated, antigen-specific tumor-infiltrating CD8+ T cells induced by a novel T cell-targeted immunotherapy, Vila-Leahey A, MacKay A , Portales-Cervantes L, Weir GM , Merkx-Jacques A, Stanford MM

Vila-Leahey A, MacKay A , Portales-Cervantes L, Weir GM , Merkx-Jacques A, Stanford MM

T cell infiltration into tumors induced by DPX-Survivac combination immunotherapy demonstrated by PET/MR imaging in an orthotopic ovarian cancer model

AACR, June 2020

T cell infiltration into tumors induced by DPX-Survivac combination immunotherapy demonstrated by PET/MR imaging in an orthotopic ovarian cancer model

Watch the presentation video

DPX platform for Drug Delivery: Evaluation of lymph node-targeted delivery of immunomodulatory agents in DPX

AACR, June 2020

DPX platform for Drug Delivery: Evaluation of lymph node-targeted delivery of immunomodulatory agents in DPX

Watch the presentation video

Human Vaccines and Immunotherapeutics, June 2020

Evaluation of the protective potential of antibody and T cell responses elicited by a novel preventative vaccine towards respiratory syncytial virus small hydrophobic protein

Torrey HL, Kaliaperumal V, Bramhecha Y, Weir GM, Falsey AR, Walsh EE, Langley JM, Schepens B, Saelens X, Stanford MM.

Infiltration of tumor by T cells following treatment with DPX-Survivac and intermittent low dose cyclophosphamide (CPA) leads to clinical responses in advanced recurrent ovarian cancer (OvCa)

ASCO, May 2020

Infiltration of tumor by T cells following treatment with DPX-Survivac and intermittent low dose cyclophosphamide (CPA) leads to clinical responses in advanced recurrent ovarian cancer (OvCa)
DPX-Survivac, a novel T cell immunotherapy, induces robust T cell responses in advanced ovarian cancer with significant anti-tumor efficacy

ASCO-SITC, February 2020

DPX-Survivac, a novel T cell immunotherapy, induces robust T cell responses in advanced ovarian cancer with significant anti-tumor efficacy
Updated Clinical Data from Phase 2 SPiReL Study Evaluating DPX-Survivac as a Combination Therapy in r/r DLBCL Presented at 61st American Society of Hematology (ASH) Annual Meeting

ASH, December 2019

Updated Clinical Data from Phase 2 SPiReL Study Evaluating DPX-Survivac as a Combination Therapy in r/r DLBCL Presented at 61st American Society of Hematology (ASH) Annual Meeting
Comprehensive Immune Profiling of Clinical Samples From Subjects With Advanced Recurrent Ovarian Cancer Treated With a Novel T Cell Activating Therapy, DPX-Survivac

SITC, November 2019

Comprehensive Immune Profiling of Clinical Samples From Subjects With Advanced Recurrent Ovarian Cancer Treated With a Novel T Cell Activating Therapy, DPX-Survivac
Safety and efficacy results of the combination of DPX-Survivac, pembrolizumab and intermittent low dose cyclophosphamide (CPA) in subjects with advanced and metastatic solid tumours (preliminary results)

ESMO, September 2019

Safety and efficacy results of the combination of DPX-Survivac, pembrolizumab and intermittent low dose cyclophosphamide (CPA) in subjects with advanced and metastatic solid tumours (preliminary results)

J Infect Dis, July 2018

A Respiratory Syncytial Virus Vaccine Based on the Small Hydrophobic Protein Ectodomain Presented With a Novel Lipid-Based Formulation Is Highly Immunogenic and Safe in Adults: A First-in-Humans Study

Langley JM, MacDonald LD, Weir GM, MacKinnon-Cameron D, Ye L, McNeil S, Schepens B, Saelens X, Stanford MM, Halperin SA. J Infect Dis.